Adjuvante perkutane Radiatio lokal fortgeschrittener papillärer und follikulärer Schilddrüsenkarzinome: Überlegungen vor dem Start einer prospektiven Multizenterstudie

Zusammenfassung

Bezüglich der adjuvanten Radiatio lokal fortgeschrittener differenzierter Schilddrüsenkarzinome gibt es weder in Deutschland noch in den USA einen allgemeinen Konsens. Die Ergebnisse der bisher vorliegenden, ausnahmslos retrospektiven Studien sind widersprüchlich. Sie erlauben jedoch die Annahme, daß zumindest ein Teil der Patienten mit organüberschreitendem Tumorwachstum nach einer R0/R1-Resektion von einer zusätzlich zur etablierten Radioiodbehandlung durchgeführten perkutanen Radiatio profitieren könnte. Die Publikation befaßt sich mit einem Literaturüberblick, illustriert die an deutschen Kliniken uneinheitlichen Vorgehensweisen und die sich daraus ergebende Notwendigkeit einer prospektiven multizentrischen Studie

Summary

Adjuvant external radiation therapy in patients with locally advanced differentiated thyroid cancer was repeatedly controversially discussed. Results of various retrospective analyses were contradictory and did not lead to a generally accepted consent. Nevertheless, they allow the assumption that at least subgroups of patients in a pT4 stage with no or microscopic residual disease may benefit from adjuvant external beam therapy. This publication is a review of the literature and illustrates the variety of “strategies” practiced in German clinical centers and the necessity of a prospective multicentric clinical trial.

Schlüsselwörter

Differenziertes Schilddrüsenkarzinom - perkutane Radiatio - Multizenterstudie

Key words

Differentiated thyroid carcinoma - external radiation - multicentric clinical trial

• LITERATUR

• 1 Benker G, Olbricht T, Reinwein D, Reiners C, Sauerwein W, Krause U, Mlynek ML, Hirche H. Survival rates in patients with differentiated thyroid carcinoma. Influence of postoperative external radiotherapy. Cancer 1990; 65: 1517-20.
• 2 Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome [see comments]. Mayo Clin Proc 1991; 66: 11-22.
• 3 Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thvroid cancer. Semin-Surg-Oncol 1999; 16: 42-9.
• 4 Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992; 164: 671-6.
• 5 Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A. Survival discriminants for differentiated thyroid cancer. Am J Surg 1990; 160: 344-7.
• 6 DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Endocrinol Metab 1990; 71: 414-24.
• 7 Farahati J, Reiners C, Stuschke M, Muller SP, Stuben G, Sauerwein W, Sack H. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996; 77: 172-80.
• 8 Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19: 545-76.
• 9 Hermanek P, Henson DE, Hutter RVP, Sobin LH. TNM Supplement 1993. A commentary on uniform use. Berlin, Heidelberg, New York, Tokyo: Springer; 1993: 51 und 22-5.
• 10 Junginger T, Härtel W. Leitlinien der Therapie maligner Schilddrüsentumoren. In: Grundlagen der Chirurgie; 1996
• 11 Leisner B, Degelmann G, Dirr W, Kanitz W, Bull U, Langhammer H, Lissner J, Pabst HW. [Therapeutic results of malignant goiter 1960-1980. Significance of percutaneous radiotherapy in well differentiated carcinomas]. Dtsch Med Wochenschr 1982; 107: 1702-7.
• 12 Lerch H, Schober O, Kuwert T, Saur HB. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 1997; 15: 2067-75.
• 13 Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer [see comments] [published erratum appears in Am J Med 1995 Feb; 98 (2): 215]. Am J Med 1994; 97: 418-28.
• 14 Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70: 511-8.
• 15 Müller-Gärtner HW, Brzac HT, Rehpenning W. Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer 1991; 67: 1903-11.
• 16 O’Connell ME, RP AH, Harmer CL. Results of external beam radiotherapy in differentiated thyroid carcinoma: a retrospective study from the Royal Marsden Hospital. Eur J Cancer 1994; 30A: 733-9.
• 17 Phlips P, Hanzen C, Andry G, Van Houtte P, Fruuling J. Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 1993; 19: 399-404.
• 18 Reinhardt M, Guttenberger R, Slanina J, Frommhold H, Moser E. [Indications for percutaneous radiotherapy in carcinoma of the thyroid gland. Freiburg consensus]. Radiologe 1995; 35: 535-9.
• 19 Samaan NA, Maheshwari YK, Nader S, Hill Jr. CS, Schultz PN, Haynie TP, Hickey RC, Clark RL, Goepfert H, Ibanez ML, Litton CE. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Endocrinol Metab 1983; 56: 1131-8.
• 20 Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Endocrinol Metab 1992; 75: 714-20.
• 21 Sautter-Bihl ML, Herbold G, Heinze HG, Bihl H. [Postoperative external radiotherapy of differentiated thyroid carcinoma: when is radioiodine therapy alone inadequate?. The dosimetric considerations with a Monte Carlo simulation], Strahlenther-Onkol 1991; 167: 267-72.
• 22 Sautter-Bihl ML. Hat die perkutane Strahlentherapie einen Stellenwert in der Behandlung des Schilddrüsenkarzinoms?. Onkologe 1997; 3: 48-54.
• 23 Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994; 18: 559-67 discussion 567-8.
• 24 Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996; 3: 534-8.
• 25 Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin-Surg-Oncol 1999; 16: 12-5.
• 26 Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR. 3rd. Prospective multicenter study of thyroidcarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group [see comments]. Cancer 1998; 83: 1012-21.
• 27 Simpson WJ, Carruthers JS. The role of external radiation in the management of papillary and follicular thyroid cancer. Am J Surg 1978; 136: 457-60.
• 28 Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Rad Oncol Biol Phys 1988; 14: 1063-75.
• 29 Smedal MI, Salzman FA, Meissner WA. The value of 3 mv. roentgen-ray therapy in differentiated thyroid carcinoma. Am J Roentgenol Radium Ther Nucl Med 1967; 99: 352-64.
• 30 Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82: 375-88.
• 31 Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thvroid cancers. Cancer 1985; 55: 2062-71.